군유전체학 시장 보고서 : 제품, 기술, 용도, 지역별(2025-2033년)

The global metagenomics market size reached USD 619.1 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 1,454.1 Million by 2033, exhibiting a growth rate (CAGR) of 9.45% during 2025-2033.

Metagenomics refers to the study of microbial genomes in the natural environment. It involves cloning of the genome to study the ecology, evolution and diversity, thereby bypassing the need for isolation and laboratory cultivation of individual species. Metagenomics uses sequencing and bioinformatics technologies to obtain scientific insights and is utilized as a molecular tool for analyzing the deoxyribonucleic acid (DNA) acquired from the environmental samples through water, soil and human waste. The samples are further processed through sequence reading, gene prediction, binning and functional annotation. The insights are used to diagnose infectious diseases, environmental remediation, gut microbe characterization and the development of biofuels.

Metagenomics Market Trends:

The increasing prevalence of virus-induced infections, such as diarrhea, influenza, hepatitis B, and HIV/AIDS, across the globe, is among the key factors driving the market growth. Moreover, the rising demand for effective solutions for the timely diagnosis of neuroinfectious diseases, such as meningitis and encephalitis, is providing a thrust to the market growth. In line with this, metagenomics also aids in identifying bacterial pathogens that can lead to foodborne disease outbreaks, which is further contributing to the growth of the market. In comparison to the traditionally used technologies, metagenomics requires a lesser number of pre-sequencing steps, enhances the authenticity of long readings and offers high read accuracy. Additionally, various technological advancements, such as the development of next-generation sequencing services, are acting as other growth-inducing factors. These solutions are integrated with data analysis software for faster data analysis and sample processing. Other factors, including extensive research and development (R&D) activities in the field of life sciences, along with the increasing utilization of metagenomics for manufacturing sustainable agricultural products, are anticipated to drive the market toward growth.

Key Market Segmentation:

Breakup by Product:

• Instruments and Software
• Consumables

Breakup by Technology:

• Sequencing
• Bioinformatics

Breakup by Application:

• Infectious Disease Diagnosis
• Environmental Remediation
• Gut Microbe Characterization
• Biotechnology
• Biofuel
• Agriculture

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Agilent Technologies Inc, Enterome, Eurofins Scientific, F. Hoffmann-La Roche AG (Roche Holding AG), Illumina Inc, Novogene Co. Ltd., Oxford Nanopore Technologies Limited, Pacific Biosciences of California Inc., PerkinElmer Inc., QIAGEN N.V., Swift Biosciences Inc. (Danaher Corporation) and Thermo Fisher Scientific Inc.

Key Questions Answered in This Report:

• How has the global metagenomics market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the global metagenomics market?
• What are the key regional markets?
• What is the breakup of the market based on the product?
• What is the breakup of the market based on the technology?
• What is the breakup of the market based on the application?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the global metagenomics market and who are the key players?
• What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Metagenomics Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product

• 6.1 Instruments and Software
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Consumables
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Technology

• 7.1 Sequencing
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Bioinformatics
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast

8 Market Breakup by Application

• 8.1 Infectious Disease Diagnosis
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Environmental Remediation
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Gut Microbe Characterization
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Biotechnology
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Biofuel
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast
• 8.6 Agriculture
  • 8.6.1 Market Trends
  • 8.6.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Agilent Technologies Inc.
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
    • 14.3.1.4 SWOT Analysis
  • 14.3.2 Enterome
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
  • 14.3.3 Eurofins Scientific
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
    • 14.3.3.4 SWOT Analysis
  • 14.3.4 F. Hoffmann-La Roche AG (Roche Holding AG)
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 SWOT Analysis
  • 14.3.5 Illumina Inc
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
    • 14.3.5.4 SWOT Analysis
  • 14.3.6 Novogene Co. Ltd.
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
  • 14.3.7 Oxford Nanopore Technologies Limited
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 SWOT Analysis
  • 14.3.8 Pacific Biosciences of California Inc.
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
  • 14.3.9 PerkinElmer Inc.
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
    • 14.3.9.4 SWOT Analysis
  • 14.3.10 QIAGEN N.V.
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
    • 14.3.10.3 Financials
    • 14.3.10.4 SWOT Analysis
  • 14.3.11 Swift Biosciences Inc. (Danaher Corporation)
    • 14.3.11.1 Company Overview
    • 14.3.11.2 Product Portfolio
  • 14.3.12 Thermo Fisher Scientific Inc.
    • 14.3.12.1 Company Overview
    • 14.3.12.2 Product Portfolio
    • 14.3.12.3 Financials
    • 14.3.12.4 SWOT Analysis